Choline salicylate is a non-steroidal anti-inflammatory drug (NSAID) and a derivative of salicylic acid, chemically classified as an organic ester salt. It acts as an analgesic, antipyretic, and anti-inflammatory agent. In the Indian context, it is primarily used in topical formulations (gels, creams) for localized pain and inflammation, such as in muscular aches, joint pain, and minor arthritic conditions. Its use as a systemic oral formulation is extremely rare and largely obsolete in modern Indian practice due to the availability of safer NSAIDs. It is considered a prodrug, as it is hydrolyzed in the body to release salicylic acid, the active moiety.
Adult: Topical only: Apply a thin layer to the affected area 3 to 4 times daily. Gently rub in. Do not apply to large areas of skin or under occlusive dressings unless directed by a physician.
Note: For external use only. Wash hands before and after application. Apply to clean, dry, intact skin. Avoid contact with eyes, mucous membranes, open wounds, or broken/irritated skin. Do not bandage tightly or use a heating pad over the applied area. If a dressing is needed, use a loose, porous one.
The therapeutic effects are primarily mediated by its active metabolite, salicylic acid. Salicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, both COX-1 and COX-2, though with less selectivity than newer NSAIDs. This inhibition blocks the conversion of arachidonic acid to prostaglandin G2 (PGG2) and subsequently to prostaglandin H2 (PGH2). The resultant decrease in prostaglandin (PG) and thromboxane synthesis mediates its anti-inflammatory, analgesic, and antipyretic actions. PGs are key mediators of pain, fever, and inflammation.
Pregnancy: Category D (US FDA). Avoid, especially in the third trimester. Salicylates may cause premature closure of the ductus arteriosus, prolonged gestation and labor, increased risk of maternal and neonatal bleeding, and potential teratogenic effects (cardiovascular, craniofacial) with first-trimester use. Topical use should also be avoided unless clearly necessary.
Driving: Unlikely to affect driving ability when used topically as directed. However, systemic absorption causing dizziness, vertigo, or tinnitus could impair performance. Patients should be cautious.
| Anticoagulants (Warfarin, Acenocoumarol) | Increased risk of bleeding due to additive antiplatelet effect and potential displacement from protein binding sites. | Major |
| Other NSAIDs (Ibuprofen, Diclofenac, Naproxen) | Increased risk of GI toxicity and reduced antiplatelet effect of low-dose aspirin. | Major |
| Methotrexate | Decreased renal clearance of methotrexate, leading to increased toxicity (myelosuppression). | Major |
| Sulfonylureas (Glibenclamide, Glimepiride) | Salicylates may potentiate hypoglycemic effect. | Moderate |
| ACE Inhibitors (Enalapril, Ramipril) | Attenuation of antihypertensive effect and potential worsening of renal function. | Moderate |
| Diuretics (Furosemide) | Reduced diuretic and antihypertensive efficacy; potential for nephrotoxicity. | Moderate |
| Valproic Acid | Displacement from protein binding, leading to increased valproate toxicity. | Moderate |
| Corticosteroids (Prednisolone) | Increased risk of GI ulceration; corticosteroids may reduce salicylate levels. | Moderate |
| Probenecid | Decreased uricosuric effect of probenecid. | Moderate |
Same composition (Choline Salicylate (NA)), different brands: